Introduction {#sec1-1}
============

After the introduction of Highly Active Anti-Retroviral Therapy (HAART) mean age and comorbidities related to ageing, immune suppression, coinfections and persistent inflammation increased in People Living with HIV (PLWH) \[[@ref1]\] \[[@ref2]\] \[[@ref3]\] \[[@ref4]\] \[[@ref5]\] \[[@ref6]\] \[[@ref7]\] \[[@ref8]\] \[[@ref9]\] \[[@ref10]\] \[[@ref11]\] \[[@ref12]\] \[[@ref13]\] \[[@ref14]\] \[[@ref15]\] \[[@ref16]\] \[[@ref17]\] \[[@ref18]\] \[[@ref19]\] \[[@ref20]\] \[[@ref21]\] \[[@ref22]\] \[[@ref23]\] \[[@ref24]\] \[[@ref25]\] \[[@ref26]\] \[[@ref27]\].

Among the coinfections commonly observed in PLWH, there is Leishmaniasis, which is still considered a neglected tropical disease, affecting immunocompromised people, and especially PLWH, more than the immunocompetent population, being responsible for 20,000 to 40,000 deaths per year \[[@ref28]\].

PLWH are considered at high-risk of developing Leishmaniasis because of the two infections geographical distribution: areas, where the HIV infection have a high prevalence, are usually also areas where the Leishmania infection is widespread \[[@ref29]\].

Despite the introduction of HAART significantly reduced the coinfection prevalence, mortality rate and relapses prevalence are still high in immunocompromised people \[[@ref29]\]\[[@ref31]\]. Prognosis is also affected by the nutritional status of the patient \[[@ref29]\].

Treatment is difficult in immunocompromised people, because of the role of both constitutive immunodepression and Leishmania-related immunodepression on the response to the infection \[[@ref28]\] \[[@ref31]\] \[[@ref32]\] \[[@ref33]\] \[[@ref34]\].

Here we present a case of HIV-Leishmania coinfection during which the patient developed some atypical signs before the appearance of a more typical Leishmaniasis clinical presentation allowed the diagnosis.

Case Report {#sec1-2}
===========

A 52-years-old HIV-positive man, followed in our outpatient clinic since 1999 for his infection, came to the Emergency Ward of our University Hospital in August 2017, complaining of diarrhoea (defined as defecation of yellow liquid faeces at least five times per day) for two months. He lived in a poor health condition setting, and he was a smoker. He always lived in Sicily and never left the island.

Until November 2015 he was on combined anti-retroviral therapy (cART) with emtricitabine/tenofovir disoproxil (FTC/TDF) and raltegravir (RAL), with successful virologic (HIV-RNA not detectable) and partially successful immunological (CD4+ 491/μl, 24%) control, but he was lost to follow-up for a year. In January 2017 he was admitted to the Thoracic Surgery Unit of our hospital for a massive left pleural effusion, drained through a chest tube. An incomplete immunological control was highlighted (CD4+ T-cells 62/ μl, 7%; CD8+ T-cells 630/ μl, 71%, CD4/CD8 0.09) at that time. Therefore, he started a cART with darunavir/cobicistat (DRV/COBI) and RAL, with a successful virologic control (HIV-RNA not detectable), and a slight improvement of his immunological control (CD4+ 82/μl, 11 %) at the last blood testing, which took place in May.

At the admission, he complained of asthenia. He reported that he had autonomously suspended cART, thinking that the diarrhoea was an adverse effect of the therapy, with no improvement. The physical examination revealed extreme dehydration and moderate hepatosplenomegaly. Moreover, a hyperemic hyperthermic painful lesion was highlighted on his left side, around the area where the chest tube was positioned in January. He was feverish (37.5 °C), while blood pressure and heart rate were normal. Blood tests showed anemia (Hb 9.9 g/dl), leukopenia (WBC 3,260/μl) and thrombocytopenia (PLTS 109,000/μl); hypoalbuminemia (1.7 g/dl); monoclonal hypergammaglobulinemia (65.58%, normal 10.5 - 19.5%). He began an intravenous (IV) therapy with albumin and IV hydration, and a cART with DRV/COBI and RAL was started again.

During the admission his conditions worsened, making it necessary to perform a blood transfusion on August, 5^th^. [Table 1](#T1){ref-type="table"} resumes altered results of the blood tests performed on our patient during the admission.

###### 

Blood test results during the admission

                   Aug, 2^nd^   Aug, 4^th^   Aug, 5^th^   Aug, 6^th^   Aug, 8^th^   Aug, 11^th^   Aug, 16^th^
  ---------------- ------------ ------------ ------------ ------------ ------------ ------------- -------------
  WBC/ μl          3.280        1.990        2.170        2.080        2.460        1.860         2.140
  N (%)            55           56           52           56           50           61            54
  N/ μl            1.810        1.114        1.128        1.165        1.230        1.135         1.156
  L (%)            38           37           43           37           44           33            40
  L/ μl            1.250        736          933          770          1.082        614           856
  CD3 (%)                       87                                                                
  CD3/ μl                       641                                                               
  CD4 (%)                       8                                                                 
  CD4/μl                        59                                                                
  CD8 (%)                       71                                                                
  CD8/ μl                       523                                                               
  CD4/CD8                       0,11                                                              
  CD19 (%)                      7                                                                 
  CD19/ μl                      52                                                                
  CD20 (%)                      5                                                                 
  CD20/ μl                      37                                                                
  CD34 gated (%)                0,02                                                              
  CD34 vital/ μl                1,96                                                              
  PLTS             109,000      91,000       71,000       74,000       87,000       103,000       138,000
  Hb (g/dl)        9,9          8,2          7,6          8,4          9,7          8,7           8,6
  CRP (mg/dl)      12,80                     6,30                      6,70         6,30          1,50
  PCT (ng/ml)                   0,44                                                              0,3
  Albumin (g/dl)   1,7                                                 2,02         2,34          2,8
  γ-globulin (%)   65,58                                               61,4         58,66         

As it can be seen, his immunological control had worsened, revealing a CD4+ T-cell count of 59/μl (8%), with a CD8+ T-cell count of 523/μl (71%) and a resulting CD4+/CD8+ ratio of 0.11.

Stool examinations (research of the *Clostridium difficile* toxin, parasitic infections and stool cultures, faecal occult blood) were performed, resulting in negative. Suspecting multiple myeloma, the patient underwent a bone marrow biopsy to determine the cause of the pancytopenia. No biopsy was performed on the flank skin lesion.

Indirect immunofluorescence assay (IFAT) and Polymerase Chain Reaction (PCR) for the research of a *Leishmania* infection were performed on the 4^th^ day after the admission, resulting in positive (PCR 11,500 Leishmania/ml; IFAT 1:5120) on the 8^th^ day after the admission.

He then began a treatment with Liposomal Amphotericin B (L-AMB) 4 mg/kg/day on days 1 to 5, according to the *Italian guidelines for the diagnosis and management of HIV infection (2016 edition)* of the Italian Society of Infectious and Tropical Diseases (ISITD), and he repeated the treatment on days 10, 17, 24, 31 and 38, completing the cycle \[[@ref35]\]. He was discharged on the 14^th^ day after the admission and completed the treatment as an outpatient. Diarrhoea and the hyperemic lesion on his flank completely disappeared after the fifth day of therapy with L-AMB. [Figure 1](#F1){ref-type="fig"} shows the Serum Protein Electrophoresis (S-PEP) trend before, during and at the end of the therapy. Secondary prophylaxis was not started, and the patient is still in follow up for the possibility of VL relapses.

![S-PEP before (A); during (B) and after completing (C) the therapy with L-AMB](OAMJMS-6-843-g001){#F1}

Discussion {#sec1-3}
==========

Leishmaniasis is a parasitic disease affecting both animals and humans, acquired with the bite of sand flies or, in Injection Drug Users (IDUs), with contaminated needles, still hypoendemic in Sicily and the Mediterranean basin \[[@ref34]\] \[[@ref36]\].

It is a known opportunistic disease in People Living with HIV (PLWH), whose immunodeficiency promotes visceral localisation, even though the coinfection prevalence reduced after the introduction of HAART \[[@ref33]\] \[[@ref36]\] \[[@ref37]\]. Moreover, *Leishmania spp* can promote viral replication and enhance progression to Acquired Immuno-Deficiency Syndrome (AIDS) \[[@ref34]\]. As a result, despite the introduction of HAART, relapses are still common, and mortality is three times higher in HIV-Leishmania coinfection than in HIV-negative people affected by Leishmania infection \[[@ref30]\] \[[@ref31]\].

Cota and al \[[@ref33]\] reported in 2017 that CD4 T-cell count at the moment of the diagnosis is not able to foresee the patient's prognosis. However, resolution of the infection depends on an efficient CD4+ T-cell response, and it was observed that a higher incidence of symptoms is related to a lower CD4+ T-cell count \[[@ref31]\] \[[@ref32]\].

The most frequent signs and symptoms of this infection are fever, asthenia, weight loss and splenomegaly; unspecific symptoms that could often lead to a delay in the diagnosis \[[@ref31]\] \[[@ref34]\]. Also, PLWH can complain of misleading non-classical symptoms \[[@ref29]\].

In our case, the patient came to our attention in January, after more than a year of likely therapeutic vacation, with a seriously impaired immunological control. At the time he did not have any classical sign of the infection (normal S-PEP, no signs of pancytopenia, no hepatosplenomegaly), but it has been reported that Leishmaniasis can be related to pleural effusion, especially in PLWH with a very low CD4+ T-cell count \[[@ref38]\]. Moreover, Infectious Diseases Society of America (IDSA) 2016 guidelines report that in PLWH the number of asymptomatic carriers of Leishmania seems to be higher than in the immunocompetent host \[[@ref39]\]. Therefore, it can be supposed that our patient's disease began some time before the classical signs appeared.

An active response to Leishmania, leading to the infection control, is associated to host adaptive immunity, but, at the same time, to natural immunity \[[@ref40]\]. The most influential factor in the immune response in Leishmaniasis seems to be the early interaction of the parasite with macrophages and dendritic cells \[[@ref41]\].

Moreover, it has been observed an enhanced secretion of Th2 cytokines, and in particular IL-10, in Visceral Leishmaniasis associated to HIV-infection, which can promote the dissemination of both the virus and the parasite \[[@ref28]\] \[[@ref32]\] \[[@ref40]\] \[[@ref41]\] \[[@ref42]\] \[[@ref43]\].

Our patient presented to our attention, both in January and August, with a profoundly impaired immunological control, defined as a very low CD4+ T-cell count and an inverted CD4/CD8 ratio, despite having a suppressed VL, a common sign during visceral Leishmaniasis \[[@ref42]\]. However, the fact the patient came from a period of therapeutic vacation made difficult to think to other causes of severe immunodepression than his HIV infection, leading to the possibility of a diagnostic delay.

The CD4/CD8 ratio is a marker of immune dysfunction leading to persistent inflammation in PLWH, and a low ratio can predict an impaired CD4+ T-cell count recovery before the start of the HAART \[[@ref44]\]. During visceral leishmaniasis, CD8+ T-cells, and especially those expressing CD38, or activated CD8+ T-cells, increase, leading to a status of chronic inflammation which results in a T cell depletion, establishing a vicious circle that worsens the immune-depression \[[@ref42]\].

Although both IDSA and ISITD guidelines recommend secondary prophylaxis with L-AMB in patients with a CD4+ T-cell count lower than 200/μl, our patient refused it \[[@ref35]\] \[[@ref39]\]. He is still in follow up for the possibility of relapses and recently completed his 5^th^ month from the end of the therapy with L-AMB.

In conclusion, visceral Leishmaniasis is an important opportunistic disease in PLWH, with a complicated differential diagnosis because of its unspecific symptoms and signs. It is even more difficult because of the possibility of atypical manifestations.

However, this parasitic disease has a high mortality rate, so it is mandatory to think about it in all the patients having a low CD4+ T-cell count and an inverted CD4/CD8 ratio under HAART.

Further studies are needed to clear the pathogenesis of the infection and to establish the duration of the secondary prophylaxis.
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